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Abstract 
Background: Bisphenol A (BPA) is used to produce polycarbonate plastics and epoxy resins
that are widely used in everyday products, such as food and beverage containers, toys and 
medical devices. Human biomonitoring studies have suggested that a large proportion of the
population may be exposed to BPA. Recent epidemiological studies have reported correlations
between increased BPA urinary concentrations and cardiovascular disease; yet the direct effects
of BPA on the heart are unknown. 
Objectives: The goal of our studies was to measure BPA’s effect (0.1-100 µM) on cardiac
impulse propagation ex vivo, using excised whole hearts from adult rats. 
Methods: We measured atrial and ventricular activation times during sinus and paced rhythms
using epicardial electrodes and optical mapping of transmembrane potential. Atrioventricular
activation intervals and epicardial conduction velocities were computed using recorded 
activation times. 
Results: Cardiac BPA exposure resulted in prolonged PR segment and decreased epicardial 
conduction velocity (0.1 – 100 µM), prolonged action potential duration (1 – 100 µM) and 
delayed atrioventricular conduction (10 – 100 µM). Importantly, these effects were observed 
after acute exposure (≤ 15 min), underscoring the potential detrimental effects of continuous
BPA exposure. The highest BPA concentration used (100 µM) resulted in prolonged QRS
intervals, dropped ventricular beats and eventually resulted in complete heart block. 
Conclusions: Our results show that acute BPA exposure slows electrical conduction in excised 
hearts from female rats. These findings emphasize the importance of examining BPA’s effect on 




     
  
  





        
         
     
  
     
        
       
        
       
      
          
         
         
         
          
            
 
         
        
          
       
Introduction 
Bisphenol A (BPA) is one of the most widely used chemicals worldwide, with over 8 million 
pounds produced each year (Vandenberg et al. 2010). BPA is a component of polycarbonate
plastics and epoxy resins, which are used in many plastic consumer products including food and 
drink containers, water pipes, thermal paper and paper products (receipts, paper towels, etc.), 
toys, safety equipment, electronics, dental monomers, medical equipment and tubing. It has been 
reported that BPA can leach from these products normal conditions (Vandenberg et al. 2007). 
Despite the increasing popularity of BPA-free plastics, BPA is still found in many consumer 
products. Indeed, human biomonitoring studies suggest that a large proportion of the population
may be exposed to BPA, including both children and adults (Calafat et al. 2005; Calafat et al. 
2008). BPA exposure rates range dramatically depending on lifestyle factors, with neonates in 
intensive care units (4.4 nM – 4 µM) and industrial workers (0.024 – 8.5 µM) having overall
higher urinary BPA concentrations (Calafat et al. 2009; Wang et al. 2012). Human serum BPA
levels are actively debated, with estimates ranging from 0.001 – 0.3 µM for adults (Kaddar et al. 
2009; Lee et al. 2008; Padmanabhan et al. 2008; Schonfelder et al. 2002; Vandenberg et al. 
2010). Patients undergoing multiple medical interventions – such as neonates in intensive care –
may have even higher levels of BPA in the blood. However, BPA serum levels have not been 
measured in this patient population.
There is evidence that increased exposure to endocrine-disruptors, such as BPA, might contribute
to the onset and progression of disease (Braun and Hauser 2011; Chapin et al. 2008; Diamanti-
Kandarakis et al. 2009; Richter et al. 2007; Vandenberg et al. 2007; vom Saal et al. 2007). 




    
       
    
          
    
       
         
          
         
       
        
      
       
         
 
         
      
          
          
        
cardiovascular disease. Higher BPA urine concentrations have been associated with an increased 
risk of coronary artery disease (Melzer et al. 2010; Melzer et al. 2012), hypertension (Shankar et
al. 2012), carotid atherosclerosis (Lind and Lind 2011), angina and myocardial infarction (Lang 
et al. 2008), and a decrease in heart rate variability (Bae et al. 2012). Although the latter is
primarily attributed to neuronal influences, decreased heart rate variability can also indicate
alterations in ion channel currents that drive pacemaker depolarization (Papaioannou et al. 2013). 
In addition, in vitro experimental studies have shown that higher concentrations of BPA
exposure modifies heart rate in isolated atrial preparations (Pant et al. 2011). Both of these
observations suggest alterations of ionic currents in nodal cells, which can influence nodal and 
bundle branch conduction. Moreover, if BPA induces ion channel alterations in atrial tissue, 
exposure will likely affect ion channels in other tissue compartments. Importantly, the effect of
BPA on heart electrophysiological function has not been examined. We aimed to systematically 
study the effect of BPA on cardiac conduction by conducting controlled experiments on excised 
whole rat hearts. These studies provide new measurements for important electrophysiological
parameters, including AV conduction and ventricular conduction velocity.
Methods 
Animals 
Experiments were conducted using excised hearts from adult female Sprague-Dawley rats (n =
12, 200-300 g, 2-3 months old), purchased from Hilltop Lab Animals (Scottsdale, PA). Studies
were limited to females, as previous reports have claimed that BPA’s cardiac effects are sex 
specific due to its estrogenic properties (Belcher et al. 2012; Yan et al. 2011). To account for the




           
       
   
      
   
        
    
  
        
      
      
   
      
      
          
       
       
     
      
 
control with all BPA measurements computed as a percent change from control (no BPA). 
Animals were housed in The George Washington University (GWU) animal care facility under 
standard environmental conditions (12:12 h light: dark cycle, 64-79°C, 30-70% humidity, corn 
cob bedding (Harlan Laboratories, Indianapolis, IN) with free access to food (2018 rodent chow
(Harlan Laboratories, Indianapolis, IN)) and carbon-filtered tap water. Animals were housed in 
groups of 2-3 animals per cage for 2 weeks prior to experimentation. All animals were treated 
humanely and with regard for alleviation of suffering. All procedures were conducted in 
accordance with the guidelines of the Institutional Animal Care and Use Committee at GWU. 
Excised heart preparation 
Hearts were excised and Langendorff-perfused with a modified Krebs Henseleit buffer (Gillis et
al. 1996), as previously described (Mercader et al. 2012). Hearts were placed in a temperature-
controlled chamber (Figure 1A) for electrical measurements. The perfusate was supplemented 
with 10 µM blebbistatin (Sigma Aldrich, St. Louis, MO) to reduce motion.
General protocol 
99+% purity BPA (Sigma Aldrich, St. Louis, MO) was prepared fresh for each experiment. A 
stock solution was prepared in 100% ethanol, and final dilutions were made directly in perfusate
media with a total ethanol concentration of 0.01-0.02% (no BPA (control) – 100 µM BPA, 
respectively). Control perfusate contained 0.01% ethanol and no BPA. Precautions were
maintained throughout the study to prevent BPA contamination from external sources (i.e., 
solutions mixed and stored in glass bottles, BPA-free Tygon and C-Flex tubing [Cole Parmer, 
Vernon Hills, IL] used for Langendorff-perfusion). However, the perfusate media was not




      
      
        
      
          
          
        
         
        
            
              
      
        
        
 
           
           
 
      
       
      
Excised hearts maintained electrophysiological function for > 3 hours with control media
perfusion (no BPA). Each study began midday and was completed in 1-2 hr; steps included: 1)
Perfuse with control media. 2) Position electrodes and electrocardiogram (ECG) leads (5-10 
min). 3) Record ECG and atrioventricular (AV) conduction signals during sinus rhythm (15 min 
equilibration period). 4) Implement pacing protocol and acquire optical signals (see below). 5)
Dilute BPA directly in perfusate media to achieve the appropriate final concentration. 6) Record 
ECG and AV conduction signals during sinus rhythm (15 min). 7) Implement pacing protocol
and acquire optical signals. 8) Repeat steps 5-7 for additional BPA concentrations. For each 
preparation, the heart was exposed to an average of three BPA concentrations added 
incrementally to the perfusate media (i.e., Animal #1: Control à 0.1 à 1 à 10 µM BPA, 
Animal #2: Controlà 1à 10à 25 µM BPA, 15 min exposure each). Each animal served as its
own control with measurements normalized to control perfusion in the same heart and expressed 
as a percent change. This allowed us to account for variations in electrode position for each 
experiment, and to reduce any influence of estrous cyclicity on cardiac conduction
measurements. 
The epicardial pacing protocol consisted of pacing the heart with 2 mA pulses (5 msec duration)
for ≥ 5 sec at 5-15 Hz pacing frequencies (incremented stepwise by 1 Hz). There was a 30 sec
interval after each pacing sequence before beginning the next. 
Electrical measurements 
AV conduction was measured as the time difference between activation recorded by each 
electrode (right atria and ventricular apex) during sinus rhythm (Figure 1A,B), as determined by 




        
       
         
         
   
    
      
      
 
           
       
     
      
         
          
      
     
     
         
  
sinus rhythm after 15 min exposure to control or BPA-containing media. Sinus heart rate
remained stable during control perfusion (4.1 ± 1 Hz), but slowed after exposure to 50–100 µM 
BPA (3.6 ± 1 Hz, 3.3 ± 1 Hz, respectively). However, this slowing did not reach significance
until the onset of AV block (described below). All electrical signals were amplified (Dagan EX4-
400 differential amplifier; Dagan Corporation, Minneapolis, MN) and recorded using a
PowerLab data acquisition system (ADInstruments, Colorado Springs, CO). Electrical signals, 
including AV delay and ECG segments, were analyzed using LabChart software
(ADInstruments, Colorado Springs, CO; n ≥ 4 signals per concentration for each independent
experiment). 
Epicardial conduction velocity (CV) measurements  
The effect of BPA on CV was studied using epicardial electrodes and optical mapping. CV is
rate-dependent and decreases at high pacing frequencies, such rate dependent changes are
referred to as CV restitution (Kleber and Rudy 2004; Qu et al. 2004). Therefore, a pacing 
protocol was implemented that gradually increased pacing frequencies (5–15 Hz) to reveal the
effect of BPA on CV. Epicardial conduction time (sec) was computed as the difference between 
the onset of the pacing pulse and the activation time measured from the apical recording 
electrode (Figure 1A). Epicardial CV (cm/sec) was computed by dividing conduction time by 
electrode separation distance. CVs were calculated for each pacing frequency (5–15 Hz, see
pacing protocol). Measurements were normalized to corresponding controls at 5 Hz pacing 
frequency (near intrinsic rate). Electrical signals were analyzed using LabChart software (n ≥ 4 




         
        
        
     
         
      
     
        
    
      
       
     
      
    
        
             
      
    
 
          
        
Optical mapping of wavefront propagation 
Optical mapping is a powerful technique for studying cardiac electrical conduction, which has
been used for more than a decade to reveal mechanisms of arrhythmia (Laughner et al. 2012). 
We used optical mapping of a potentiometric dye (RH237, Life Technologies, Carlsbad, CA) to 
study alterations in electrical conduction using techniques developed in our laboratory (Asfour et
al. 2011; Kay et al. 2006; Swift et al. 2008). RH237 dye kinetics are faster than changes in 
transmembrane potential during an action potential (Rosenbaum and Jalife 2001), and RH237
has been used successfully in our laboratory to study cardiac electrical activity. RH237 was
administered to the aorta (5 mL of a 10 µM solution) before beginning a pacing protocol
(described above). To record optical action potentials, the epicardium was illuminated using an 
LED spotlight (530/35 nM, Mightex, Pleasanton, CA). RH237 fluorescence was longpass
filtered at 680nm and imaged using a CCD camera (Ixon DV860, Andor Technology, Belfast,
UK), as previously described (Mercader et al. 2012). At each pacing frequency, optical signals
were acquired and mapping data was quickly viewed to verify continuous elliptical wavefront
propagation originating from the pacing electrode. Activation times were identified for each 
pixel and local CVs were computed (Bayly et al. 1998) to generate isochronal maps. An average
CV was computed by averaging the values of individual CV vectors across the epicardial field of
view. Optical action potentials were analyzed using custom Matlab software (MathWorks, 
Natick, MA) to measure action potential duration at 90% (APD90), depolarization and 
repolarization times.
Statistical analysis 
All values are presented as mean ± SEM, unless otherwise noted, with p < 0.05 considered 




        
     
            
    
       
       
   
      
    
       
       
       
         
    
        
     
   
media perfusion, before the addition of BPA. The lowest dose showing a statistically different
effect (p < 0.05) was determined according to one-way or two-way ANOVA, followed by paired 
t-tests (Bokkers and Slob 2005). All results were computed from a minimum n ≥ 3 independent
experiments/animals for each BPA dose examined (see Table 1).
Additionally, one-way ANOVA was performed to ensure that significant differences in cardiac
conduction were not present between control animals during control media perfusion, including 
maximum pacing frequency and conduction velocity (p > 0.05, data not shown).
Results 
Exposure to BPA prolongs atrioventricular conduction delay 
AV conduction delay was measured throughout sinus rhythm, during both control and BPA
exposure. AV conduction delay remained stable during control perfusion, but lengthened 
significantly after BPA exposure, beginning at 10 µM (Figure 1B and C). For example, AV
conduction increased by 7.5% for 10 µM BPA and 26% for 25 µM BPA exposure. Exposure to 
100 µM BPA resulted in sustained and complete AV block (see Supplemental Material, Figure
S1). Therefore at 100 µM BPA, conduction delays were computed immediately before the onset
of AV block, which usually happened within minutes. AV conduction delays were confirmed by 
measuring the PR segment time in the ECG, which lengthened after 15 min of BPA exposure at 
all concentrations. For example, PR segment time increased by 8% for 0.1 µM BPA and 14% for 




        
          
   
    
   
          
        
      
        
         
      
     
          
       
      
    
        
        
    
   
Heart block after exposure to high BPA concentrations 
Exposure to 100 µM BPA resulted in 3rd degree AV block. This was detected by dropped 
ventricular beats, where atrium impulses failed to propagate to the ventricles (see Supplemental
Material, Figure S1). Ventricular activation then resumed and was driven by an accessory
pacemaker; changes in QRS morphology and lengthening were also detected in ECG recordings.
Exposure to BPA slows ventricular CV  
Two-way ANOVA indicated that both pacing frequency and BPA concentration caused 
significant reductions in CV from control (p < 0.0001). The interaction of BPA and pacing 
frequency was also significant (p < 0.001), indicating that BPA altered the CV restitution 
properties of the tissue. At lower BPA concentrations (0.1–50 µM), significantly reduced CVs
were observed at high pacing rates (Figure 2A). For example, CV for 0.1 µM BPA was 94% of
control while pacing at 11 Hz. CV for 10 µM BPA was 94% of control at 7 Hz, which dropped
to 86% while pacing at 11 Hz. No significant reduction in CV was measured between pacing 
frequencies during control perfusion (Figure 2B). In contrast, BPA exposure significantly 
reduced CVs, even at pacing frequencies near the intrinsic heart rate (Figure 2B). Each stimulus
pulse for pacing rates from 5–15 Hz initiated a beat (1:1 capture) during control and 0.1–10 µM 
BPA perfusion. However, higher BPA concentrations (25–100 µM) reduced the maximum
frequency of 1:1 capture (Figure 2C, left), indicating an increased refractory period. In these
instances, CV was calculated using the last captured signal from a train of successfully 
propagated impulses (Figure 2C, right). Importantly, we did not detect significance in maximum
pacing frequency or conduction velocity measurements between animals during control




        
        
    
            
      
      
       
     
       
    
          
       
   
        
       
         
            
       
            
      
Optical mapping data confirmed that paced beats propagated as elliptical wavefronts that
emanated from the pacing electrode, even at high BPA concentrations. An example of this is 
shown in Figure 2D, which illustrates reduction in CV after only 1 min exposure to 100 µM 
BPA. When the lengths of individual CV vectors across the epicardial field of view were
averaged, it revealed a reduction of ventricular CV by 21% across the epicardial surface.
BPA exposure prolongs ventricular APD 
Exposure to increasing BPA concentrations resulted in slowed CV in a rate-dependent manner, 
which suggested alterations in the kinetics of membrane depolarization and/or repolarization. 
Time intervals of depolarization and repolarization were measured using optical action potentials
(Figure 3A). We found that APD90 was significantly prolonged (1–100 µM BPA), in a
concentration-dependent manner (Figure 3B). For example, APD90 increased by 7% for 1 µM 
BPA and 44% for 25 µM BPA. Results from 100 µM BPA revealed a larger relative change in 
repolarization time (98% after 3rd degree AV block, Figure 3C) than depolarization time (44% 
after 3rd degree AV block, Figure 3D). 
Discussion 
Although the toxic effects of BPA on reproduction and development have been reported, a link 
between BPA exposure and cardiovascular disease was made only recently (Lang et al. 2008;
Lind and Lind 2011; Melzer et al. 2010; Melzer et al. 2012; Shankar et al. 2012). Only a handful
of studies have examined BPA’s adverse cardiac effects and none have described the adverse
effects of BPA on electrical conduction within intact hearts. Studies using isolated atrial
preparations showed that exposure to high concentrations of BPA decreased heart rate via a nitric




       
 
        
      
       
        
         
        
       
     
        
      
       
          
  
      
    
       
       
     
        
    
myocytes to show that BPA exposure (.001 - 1 nM), when coupled with 17β-estradiol treatment, 
modified calcium handling (Yan et al. 2011). 
Our studies were designed to show the dose-response relationship of BPA on whole-heart
conduction abnormalities in female rats. We observed changes in cardiac conduction beginning
at 0.1 µM BPA. This concentration is within the range of previously reported human urinary 
concentrations (0.024–8.5 µM, Table 1), and is within the upper limit of measured human serum
levels (0.001–0.3 µM) in high-risk populations (Calafat et al. 2009; Kaddar et al. 2009; Lee et al. 
2008; Padmanabhan et al. 2008; Schonfelder et al. 2002; Vandenberg et al. 2010; Wang et al. 
2012). Such concentrations may be present in individuals chronically exposed to high levels of
BPA (i.e., industrial workers) and those with reduced metabolic capacities (i.e., prenatal, 
neonatal individuals). Although BPA is not considered a persistent compound, there is
controversy regarding whether or not BPA is immediately cleared from the body (Teeguarden et
al. 2012; Vom Saal et al. 2012). Importantly, we observed changes in cardiac conduction 
following acute (≤ 15min) BPA exposure, a time frame that is significantly less than BPA’s
reported half life (Shin et al. 2004; Volkel et al. 2002).
We observed significant, although modest changes in cardiac conduction beginning at 0.1 µM 
BPA. Notably, small changes in ion channel expression and/or electrical conduction can lead to 
pathological outcomes (Amin et al. 2010, Grant 2009). At low micromolar concentrations (10 
µM) of BPA we observed a concentration-dependent slowing of AV conduction that began 
within 15 min of exposure (Table 1). AV conduction delay was confirmed by measuring PR 
segment time, with delays beginning at 0.1 µM BPA. We also found that BPA exposure resulted 




          
          
       
         
        
       
        
          
      
      
      
   
         
        
        
       
     
     
         
          
      
is rate-dependent and is reduced at high pacing frequencies, a phenomenon known as CV
restitution that is primarily established by the recovery kinetics of sodium channels (Kleber and 
Rudy 2004; Qu et al. 2004). We observed CV slowing at high pacing rates in control
measurements as well as a significantly greater slowing of CV after BPA exposure. High pacing 
frequencies mimic increased heart rates, which could result from increased work/exercise or 
stress. When heart rates are elevated, individuals with increased BPA exposure could be
susceptible to adverse cardiac effects, including electrical conduction that is slower than normal.
In our studies we also observed that the maximum heart rate that could be achieved was
significantly reduced after BPA exposure. For example, at 25 µM BPA maximum pacing 
frequency was reduced from 15Hz to 12.8Hz. This result indicates an increased refractory 
period, which could be caused by prolonged sodium channel inactivation resulting from reduced 
potassium current and longer action potential duration (Jalife et al. 2009).
BPA’s cardiac effects were pronounced at high concentrations. 100 µM BPA exposure resulted 
in complete AV block and QRS interval widening, which is consistent with slowed ventricular 
conduction that may be attributed to reduced gap junction conductance (Gillum et al. 2009), 
reduced sodium channel activity, and activations that originate outside the specialized 
conduction system. We also detected a lengthening in APD90, with a larger relative change in 
repolarization time than depolarization time. This indicates that BPA-induced tissue
refractoriness could be the dominant mechanism of conduction failure at high concentrations and 
pacing rates. We recognize that cardiac exposure to 100 µM BPA exceeds a clinically relevant




       
   
             
     
           
      
      
      
        
     
        
        
  
            
          
        
          
          
       
         
          
 
mechanisms on the conduction system that can be examined further and also allow for direct
comparison with previously reported mechanical effects (Pant et al. 2011).
The significance of these results is that alterations in electrical conduction is a mechanism of
reentrant arrhythmias (Roden 1996), which can cause tachycardia and fibrillation in both the
atria and ventricles. The effects of BPA exposure that we observed, even at low BPA
concentrations, could be symptomatic at high hearts rates, particularly in elderly patients whose
hearts tend to be larger and more fibrotic (Biernacka and Frangogiannis 2011). In addition, 
action potential prolongation is a common mechanism of conduction block, particularly at high 
heart rates (“rate-dependent block”), and is known to be a trigger for reentrant arrhythmias
(Rosenbaum et al. 1973). Reduced conduction velocity may also cause reentrant arrhythmias, 
particularly in patients with dilated hearts (Akar et al. 2004). These adverse effects are important
even though we did not observe such arrhythmias in our studies, which is most likely the result
of the small size of the rat heart and it’s intrinsically low susceptibility to arrhythmias.
Our studies compliment previous studies of the effect of BPA on mechanical function. One result
of those studies was that BPA-induced mechanical dysfunction is gender-specific due to BPA’s
estrogenic properties (Belcher et al. 2012; Yan et al. 2011). As in these previous studies, each 
animal served as its own control in our studies to minimize any potential effects of estrous
cyclicity. This reduced the influence of the estrous cycle on measurements of cardiac conduction, 
as evidenced by a lack of statistical significance in measurements between animals during 
control perfusion (ANOVA, p > 0.05, data not shown). As a result, our paired-animal controlled 
studies in excised hearts provide new data that reveal slowing of cardiac electrical conduction 




   
         
      
       
       
     
       
      
 
            
     
     
      
           
        
            
         
        
          
       
          
     
Such impaired electrical conduction may potentially be attributed to BPA’s interaction with ion 
channels and/or estrogen receptors (Figure 4, and Supplemental Material, Table S1). BPA can
bind directly to and block the Nav1.5 sodium channel (O'Reilly et al. 2012), which is responsible
for phase 0 depolarization in ventricular myocytes (Figure 4, mechanism 1). Inhibition of the fast
sodium current by BPA would certainly reduce ventricular CV. BPA can also activate Maxi-K 
channels in coronary smooth muscle (2; Asano et al. 2010). A similar interaction with 
sarcolemma potassium channels could hyperpolarize cardiomyocytes and decrease cardiac
excitability. Modifications in either sodium or potassium channel current could also explain the
increased tissue refractoriness we observed at high pacing frequencies. 
Since BPA is classified as a xenoestrogen, it is plausible that the impaired cardiac conduction we
observed was mediated by its interaction with estrogen receptors (ER) and the resultant
downstream pathways. Animals that undergo ovariectomy have shortened PR intervals and 
shorter ventricular refractory periods (Saba et al. 2002). These observations can be explained by 
the effects of ER agonists on multiple ion currents. ER agonists can inhibit voltage-gated sodium
current (3; Wang et al. 2013) and decrease potassium current, which can prolong APD and 
repolarization time (4; Berger et al. 1997; Kurokawa et al. 2008; Nakajima et al. 1999; Tanabe et
al. 1999). ER agonists can also decrease L-type calcium current (5; Jiang et al. 1992; Meyer et al. 
1998; Nakajima et al. 1999), which can prolong ventricular APD (Berger et al. 1997; Tanabe et
al. 1999). Since L-type calcium current is the primary depolarizing current in sinoatrial and AV
nodal cells, a reduction in calcium current can lead to AV block (Hancox and Mitcheson 1997;
Kawai et al. 1981). Similar to other ER agonists (Jiang et al. 1992; Liew et al. 2004), BPA has




         
         
  
          
        
       
        
        
      
  
            
      
           
      
        
      
     
        
        
      
  
and/or activation of the nitric oxide/cGMP pathway (6; Belcher et al. 2012; Pant et al. 2011). An 
increase in nitric oxide levels can also attenuate L-type calcium current (Han et al. 1997), which 
could be an important mechanism for dropped beats and AV block at high BPA concentrations.
Conclusion 
Our results show that acute BPA exposure alters electrical conduction in excised hearts from
female rats. This could be the result of blocking the Nav1.5 sodium channel, reduced gap 
junction conductance, reduced calcium channel opening due to a nitric oxide/cGMP pathway, 
and/or inhibition of potassium channels via BPA’s estrogenic properties. Due to the complex 
interactions between these pathways (Figure 4), additional studies are needed to fully identify the
mechanisms responsible for BPA’s effects, and to determine whether these mechanisms differ by 
exposure levels and treatment time.
One limitation of the current study is that the effects of BPA on cardiac conduction were
examined following acute ex vivo exposure. Whether such conditions are relevant to chronic in 
vivo exposure is not yet known, and requires additional studies. These additional experiments are
important because BPA may motivate conduction abnormalities in individuals with pre-existing 
heart conditions, such as AV conduction dysfunction, disease of the cardiac electrical conduction 
system, or fibrosis of the atrial and/or the ventricles. Other high-risk populations, such as
industrial workers, prenatal and neonatal patients with reduced metabolic capacity, and elderly 
patients with substantial cardiac fibrosis may also be affected. Overall, our findings emphasize
the importance of examining BPA’s effect on heart electrophysiology and determining whether 
chronic in vivo exposure can cause/exacerbate conduction abnormalities in patients with pre-
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N N N N Y Y Reduced Ca+2 current
in SA node cells
AV delay N N Y Y Y Y Reduced Ca+2 current
in AV node cells
Prolonged PR
segment
Y Y Y Y Y Y Impaired conduction




Y Y Y Y Y Y Reduced Na+2 
current and gap
junction conductance





N N N Y Y Y Increased ventricular 
refractoriness due to
long APD
Significant changes (p<0.05) in parameter differences from control/untreated are denoted with a “Y”.
Insignificant changes are denoted with an “N”. Potential primary mechanisms for the effect of BPA on
measured parameter differences are listed in the last column. As a reference, BPA dose ranges correspond
to clinical levels in blood (0.1 – 1 µM), in urine (0.1 – 10 µM) and concentrations typically used in
toxicological studies (0.1 – 100 µM). The number of independent experiments/animals examined is






         
   
     
   
   
   
    
 
         
         
    
        
         
 
    
   
 
Figure Legends
Figure 1. BPA exposure prolongs AV conduction. A. Heart preparation and electrode placement. 
LA = left atrium, RA = right atrium, RA Record = right atrium recording electrode, V Record =
ventricle recording electrode B. AV conduction delay following control, 10 µM and 100 µM 
BPA exposures. C. Left: Time course showing AV delay following BPA exposure. Right: AV 
delay measured after 15 min treatment (0.1–50 µM). D. Left: PR segment elongation following 
exposure to 10 µM BPA. Right: PR segment prolongation measured after 15 min treatment. 
Measurements for 100 µM BPA were prior to the onset of AV block (indicated by circle). (n ≥ 3, 
*p < 0.05). Dose response determined by one-way ANOVA; lowest dose with significance was
determined by paired t-tests.
Figure 2. BPA reduces ventricular CV. A. Reduced CVs at high pacing frequencies (7–11 Hz; n
≥ 3). 0.1 µM is significantly different at 9 and 11 Hz (*p < 0.05), but not 7 Hz (p = 0.054). All
data points (1-100 µM) are significantly different (**p < 0.05). B. CV slowing for 10 and 100 
µM BPA with increasing pacing frequency (n ≥ 3, *p < 0.05). C. Left: Exposure to higher BPA
concentrations reduced the maximum rate of ventricular activation (n ≥ 3, *p < 0.05). Right: CV
was calculated using the last captured signal (denoted by ‡). Pacing spikes are indicated by the ↓. 
The large arrow indicates loss of capture. D. Wavefront propagation across the ventricular 
epicardium (9 Hz). Local CVs are shown as arrows. Left: Control perfusion. Right: 1 min 
exposure to 100 µM BPA. Dose response determined by 1- or 2-way ANOVA; lowest dose with 




      
   
          
    
 
   
    
 
  
    
  
         
  
 
Figure 3. BPA prolongs ventricular APD90. A. Optical action potentials from ventricular tissue
(8 Hz). AUF = arbitrary units of fluorescence. B. APD90 was prolonged following BPA exposure
(n ≥ 3, *p < 0.05), likely due to longer repolarization (C) and depolarization time (D) (n ≥ 3, *p
< 0.05). Dose response determined by one-way ANOVA; lowest dose with significance was
determined by paired t-tests.
Figure 4. Possible mechanisms underlying BPA’s impairment of cardiac conduction. BPA
binding can (1) block voltage-gated sodium channels, or (2) activate maxi-K+ channels (located 
in the mitochondria of cardiomyocytes, or in sarcolemma of cardiac neurons and endothelial
cells). (3) ER agonists can inhibit sodium current via activation of PKC-PKA pathway. (4) ER 
agonists can inhibit potassium current. (5) ER agonists can inhibit L-type calcium current via
NO/cGMP/PKG pathway, which acts as an antagonist to cAMP activation. This effect is
concentration dependent, as NO can activate calcium channels at basal concentrations. (6) BPA
can reduce cardiac contractility, an effect that is also dependent upon NO concentration. (see 
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BPA, M Max pacing frequency (Mean + SD)
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Figure 4 
AC = adenylate cyclase    NO = nitric oxide  
AKT = protein kinase B   NOS3 = nitric oxide synthase 3  
cAMP = cyclic adenosine monophosphate PKA = protein kinase A 
cGMP = cyclic guanosine monophosphate  PKC = protein kinase C 
DAG= diacylglycerol   PKG = protein kinase G 
PI3K= phosphoinositide 3-kinase  PLC = phospholipase C 
  
